Biotech in Belgium: news and updates

News and Trends 16 Jun 2022

Gimv creates new fund for life science companies

European investment company Gimv has launched its fifth investment platform with a focus on venture capital investments in innovative life sciences companies. Gimv said after growth in its existing healthcare platform, a dedicated life sciences platform will strengthen its role in the international life science venture capital ecosystem. The company added its key investment focus […]

June 16, 2022 - 2 minutesmins - By Jim Cornall

radiopharmaceutical treatments precirix jeito

News and Trends 17 Mar 2022

€80M Series B Establishes European Champion in Radiopharmaceuticals

Big European venture capital firms Jeito, Forbion, and Inkef Capital have teamed up to propel the local radiopharmaceutical scene by investing €80M in the Belgian firm Precirix. Europe has a long history of expertise in the development of radiopharmaceutical drugs. One of the pioneers in the field was Advanced Accelerator Applications (AAA) in France. AAA […]

March 17, 2022 - 4 minutesmins - By Jonathan Smith

Belgium biotech vc fund newton biocapital japan

News and Trends 18 Feb 2022

Belgian VC Fund Leads Investment Wave in Japanese Biotech

As US and European investor interest in Japanese biopharma startups spikes, the Belgian venture capital firm Newton Biocapital has launched a €150M fund to harness synergy between European and Japanese life sciences. Japan boasts a world-class technology industry in addition to a thriving life sciences scene. The nation hosts large companies including Takeda, Eisai, and […]

February 18, 2022 - 4 minutesmins - By Jonathan Smith

argenx efgartigimod treatment autoimmune disease myasthenia gravis

News and Trends 21 Dec 2021

Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease

US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening up its developer argenx to billion-dollar revenues. Efgartigimod, to be marketed as Vyvgart, is an antibody fragment drug for use in adults with generalized myasthenia gravis. The FDA’s decision represents the first successful drug approval […]

December 21, 2021 - 4 minutesmins - By Anita Chakraverty

News and Trends 30 Jun 2021

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with iTeos earlier this month centered on an antibody drug that blocks an immune checkpoint called TIGIT. The candidate is currently in phase I testing for […]

June 30, 2021 - 5 minutesmins - By Victor Kotsev

Ziphius Vaccines Covid 19 pandemic vaccine treatment

News and Trends 1 Jun 2021

Next-Generation mRNA Vaccine Technology Unveiled in Series A Round

Messenger RNA vaccines have been at the forefront of the global struggle against the Covid-19 pandemic over the past year. Now scientists are working to upgrade the technology: enter the stage of saRNA, or self-amplifying RNA vaccines. Among the frontrunners to introduce saRNA technology is the Belgian startup Ziphius Vaccines, which recently raised €29.3M to […]

June 1, 2021 - 4 minutesmins - By Victor Kotsev

News and Trends 30 Jul 2020

Llama-Derived Nanobodies Join the Fight Against Covid-19

Newly-launched Belgian startup ExeVir Bio will develop ‘nanobodies’ that bind very precisely to key areas of the Covid-19 virus and other coronaviruses after raking in €23M in Series A. Based in Ghent, Belgium, ExeVir Bio is a spin-out of the research institute VIB established with the help of life sciences investor Fund+. Other investors include […]

July 30, 2020 - 3 minutesmins - By Victor Kotsev

microfluidics lab on a chip miDiagnostics

Startup Scout 1 May 2020

Belgian Company Harnesses Lab-on-a-Chip Technology to Diagnose Disease

The Belgian startup miDiagnostics is developing technology to diagnose diseases quickly, accurately, and at the point-of-care using a silicon lab-on-a-chip and nanoscale-precision microfluidics. Having good diagnostics in place can save lives. This principle is especially true in times of crisis, such as the current coronavirus pandemic. However, producing good diagnostics isn’t a simple task. In […]

May 1, 2020 - 4 minutesmins - By Jonathan Smith

News and Trends 2 Apr 2020

iTeos Therapeutics’ Cancer Immunotherapy Boosted with €114M Funding

An oversubscribed Series B2 round has seen the biopharmaceutical company iTeos Therapeutics raise €114M, which will be used to advance the clinical development of its two lead cancer immunotherapies. The funds follow on from €65M raised by iTeos in Series B financing in 2018. Since then, the Belgian company has completed a phase I trial […]

April 2, 2020 - 3 minutesmins - By Laura Cowen

Startup Scout 13 Mar 2020

This Startup Hits Hidden Proteins to Make Cancer Immunotherapies

With one foot in Belgium and another in the US, Orionis Biosciences combines US and European talent to develop cancer immunotherapies targeting difficult protein targets. Mission: To fight cancer with two technologies. The first is modifying immune proteins called cytokines to trigger the body to produce specific immune cells against a tumor. The second is […]

March 13, 2020 - 4 minutesmins - By Jonathan Smith

News and Trends 19 Feb 2020

Belgian Biotech Raises €50M to Make Gene Therapy Manufacturing Cheaper

An equity investment worth up to €50M will push to market Univercells’ manufacturing technology, which is designed to reduce the costs of viral vector production for gene therapies. The investment comes from Gamma Biosciences, an investment platform supported by the US investor KKR. Gamma Biosciences aims to acquire and invest in businesses developing gene and […]

February 19, 2020 - 2 minutesmins - By Jonathan Smith

pdcLine Pharma dendritic cell cancer vaccine

News and Trends 22 Jan 2020

Off-The-Shelf Lung Cancer Vaccine Clinical Trial Gets €20M Boost

The French-Belgian company PDC*Line Pharma has raised a €20M Series B round to fund an ongoing phase I/II trial of its off-the-shelf therapeutic vaccine for lung cancer. The total €20M consists of €13.9M in equity investments and €6.1M in loans and subsidies from the Walloon Region of Belgium. PDC*Line’s current investors took part in the […]

January 22, 2020 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us